"Ki-1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of the Ki-1 antigen in hematopoietic malignancies make it clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D017730
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.072 D23.050.285.025 D23.101.140.055
|
| Concept/Terms |
Ki-1 Antigen- Ki-1 Antigen
- Antigen, Ki-1
- Ki 1 Antigen
- CD30 Antigens
- Antigens, CD30
- Ber-H2 Antigen
- Antigen, Ber-H2
- Ber H2 Antigen
- TNFRSF8 Receptor
- Receptor, TNFRSF8
- Antigens, Ki-1
- Antigens, Ki 1
- Ki-1 Antigens
- Ki 1 Antigens
- Tumor Necrosis Factor Receptor Superfamily, Member 8
- CD30 Antigen
- Antigen, CD30
- Ber-H2 Antigens
- Antigens, Ber-H2
- Ber H2 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Ki-1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "Ki-1 Antigen".
This graph shows the total number of publications written about "Ki-1 Antigen" by people in this website by year, and whether "Ki-1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ki-1 Antigen" by people in Profiles.
-
Validation of a CD30 Enzyme-Linked Immunosorbant Assay for the Rapid Detection of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Aesthet Surg J. 2020 01 29; 40(2):149-153.
-
Challenges in the Diagnosis of Gray Zone Lymphomas. Surg Pathol Clin. 2019 Sep; 12(3):709-718.
-
Characterization of primary cutaneous CD8+/CD30+ lymphoproliferative disorders. Am J Dermatopathol. 2015 Nov; 37(11):822-33.
-
Single-Fraction Radiotherapy for CD30(+) Lymphoproliferative Disorders. Biomed Res Int. 2015; 2015:629587.
-
CD30(+) cutaneous lymphoproliferative disorders with pseudocarcinomatous hyperplasia are associated with a T-helper-17 cytokine profile and infiltrating granulocytes. J Am Acad Dermatol. 2015 Mar; 72(3):508-15.
-
STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia. 2013 Nov; 27(11):2244-7.
-
Epithelioid hemangioma (angiolymphoid hyperplasia with eosinophilia) arising on the extremities. J Cutan Pathol. 2010 Oct; 37(10):1045-52.
-
Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary? Hum Pathol. 2008 Sep; 39(9):1331-40.
-
Clinicopathologic challenge. Regional lymphomatoid papulosis, type A. Int J Dermatol. 2007 Sep; 46(9):905-9.
-
Herpes simplex virus-induced, death receptor-dependent apoptosis and regression of transplanted human cancers. Cancer Sci. 2004 Dec; 95(12):990-8.